Shares of Apellis Pharmaceuticals (NASDAQ: APLS) surged in morning trading on Monday after a Bloomberg report that larger pharma companies could be interested in the biotech firm focused on rare diseases and ophthalmology.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The report stated that Apellis is speaking to advisors regarding its options following the takeover interest. Bloomberg added that the company ”may also consider seeking partnerships or licensing agreements for some of its ophthalmology products.”
The deliberations are ongoing and the company currently prefers to stay independent.
Analysts rate APLS stock a Strong Buy based on nine Buys and two Holds.